A leader in research tools and clinical diagnostic development asked us to evaluate the opportunity for an ultrasensitive detection platform in methylation analysis.

DeciBio charactered the current and future methylation analysis landscape, defining primary use cases and users as well as key pain points with current technologies

prioritized application areas for the client’s specific detection platform based on the platform’s unique value proposition and technical specifications

built a 5-year model to project the market size and client’s market share in the methylation analysis market

Discovery and innovation start here. Understanding the market and opportunity for novel research solutions requires an uncompromising mastery of the science, engineering, and marketplace. This is where DeciBio comes in.

Diagnostics will win the war on disease. From screening to surveillance, digital to DNA, and everything in between, diagnostic developments will improve all aspects of wellness and disease management. DeciBio works with all types of diagnostic companies and technologies to make this a reality.

Life science investors understand the rewards of investing in innovation. DeciBio understands what it takes to win in these markets.